GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortress Biotech Inc (NAS:FBIO) » Definitions » Capex-to-Operating-Income

Fortress Biotech (Fortress Biotech) Capex-to-Operating-Income : 0.00 (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Fortress Biotech Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Fortress Biotech's Capital Expenditure for the three months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-22.76 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Fortress Biotech Capex-to-Operating-Income Historical Data

The historical data trend for Fortress Biotech's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortress Biotech Capex-to-Operating-Income Chart

Fortress Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Fortress Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Fortress Biotech's Capex-to-Operating-Income

For the Biotechnology subindustry, Fortress Biotech's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fortress Biotech's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fortress Biotech's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Fortress Biotech's Capex-to-Operating-Income falls into.



Fortress Biotech Capex-to-Operating-Income Calculation

Fortress Biotech's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-8.098) / -142.342
=N/A

Fortress Biotech's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -22.757
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fortress Biotech  (NAS:FBIO) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Fortress Biotech Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Fortress Biotech's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Fortress Biotech (Fortress Biotech) Business Description

Traded in Other Exchanges
Address
1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.
Executives
Rosenwald Lindsay A Md director, 10 percent owner, officer: PRESIDENT, CEO & CHAIRMAN 375 PARK AVE, NEW YORK NY 10152
Lucy Lu director THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
David Jin officer: Chief Financial Officer C/O AVENUE THERAPEUTICS, INC., 1140 AVENUE OF THE AMERICAS, FLOOR 9, NEW YORK NY 10036
Dov Klein director C/O FORTRESS BIOTECH, INC., 3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK NY 10019
Robyn Hunter officer: Chief Financial Officer 95 SAWYER ROAD, SUITE 110, WALTHAM MA 02453
Eric K Rowinsky director IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014
Malcolm Hoenlein director 750 LEXINGTON AVENUE, NEW YORK NY 10022
Michael S Weiss director, 10 percent owner, officer: EXECUTIVE VICE CHAIRMAN 750 LEXINGTON AVE, NEW YORK NY 10022
J Jay Lobell director 365 W END AVE, APARTMENT 10A, NEW YORK NY 10024
Jimmie Harvey director 3741 EAST FAIRWAY DRIVE, BIRMINGHAM AL 35213
Kevin Lorenz director C/O NUVEEN, 333 W. WACKER DR., CHICAGO IL 60606
George Avgerinos officer: SVP, Biologics Operations C/O CORONADO BIOSCIENCES, INC., 24 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Kevin Horgan other: Former Chief Medical Officer C/O SOLIGENIX, INC., 29 EMMONS DRIVE, STE. C-10, PRINCETON NJ 08540
David Jonathan Barrett director ONE PENN PLAZA, SUITE 2514, NEW YORK NY 10119
Harlan F Weisman director C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803

Fortress Biotech (Fortress Biotech) Headlines

From GuruFocus

Fortress Biotech Appoints David Jin as Chief Financial Officer

By PurpleRose PurpleRose 07-22-2022

Fortress Biotech Appoints Lucy Lu, M.D., to its Board of Directors

By Value_Insider Value_Insider 12-19-2022